Lawrence C. Fritz, Ph.D.
Larry Fritz is a scientist/entrepreneur with over 25 years of experience in the biotechnology industry and has founded or co-founded multiple companies in different therapeutic areas. He was CEO and co-Founder of Incro Pharmaceuticals, a biopharmaceutical company focused on the control of programmed necrosis for the treatment of degenerative and inflammatory diseases, and which was acquired by Denali Therapeutics in 2015. Prior to Incro he was founder, President and CEO of Covella Pharmaceuticals, a company focused on alpha1 integrin, a novel adhesion molecule target for the treatment of autoimmune diseases. Covella was acquired in 2010 by Santarus, Inc. Prior to Covella, he founded Conforma Therapeutics and served as its President and CEO from inception through its acquisition by Biogen Idec in 2006. Conforma pioneered a new approach to cancer therapy, developing drugs that induce tumor cells to degrade their deregulated signaling proteins. Dr. Fritz was also a founder and Director of Cabrellis Pharmaceuticals, a specialty pharma cancer company spun-out from Conforma; Cabrellis was subsequently acquired by Pharmion Corporation. Prior to Conforma, Dr. Fritz co-founded both Athena Neurosciences, which was acquired by Elan Corporation, and Idun Pharmaceuticals, subsequently acquired by Pfizer. As Vice President of Research at Athena, his work led to the successful development of Tysabri® for multiple sclerosis, Myobloc® for neuromuscular disorders, and new approaches to the treatment of Alzheimer’s disease. While Executive Vice President, Research at Idun, he led R&D teams that pioneered pharmaceutical applications in the field of apoptotic cell death. These efforts led to new approaches to the treatment of liver diseases and cancer.
In addition to his work in start-up biotechnology companies, Dr. Fritz also served as President and CEO of Anadys Pharmaceuticals, a NASDAQ-listed public company (subsequently acquired by Roche) developing drugs for viral diseases and oncology, and as President and CEO of Auspex Pharmaceuticals (subsequently acquired by Teva), developing drugs for Huntington’s Disease and other movement disorders and which led to the successful launch of Austedo®. He is a member of the Board of Directors of Olema Pharmaceuticals and Spiral Therapeutics and a member of the Scientific Advisory Board of Dolby Family Ventures. He holds an A.B. Magna Cum Laude with Highest Honors in Biochemical Sciences from Harvard, an M.Sc. in Physiology from University College London, and a Ph.D. in Biophysics from The Rockefeller University.